Tag: Sorrento Therapeutics

December 1, 2019

5 Top NASDAQ Biotech and Pharma Stocks: Sorrento Climbs

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
November 25, 2019

Sorrento Therapeutics Rejects Unsolicited Acquisition Proposal

Sorrento Therapeutics has announced it received — and rejected — an unsolicited all cash acquisition proposal from two companies.
October 6, 2019

5 Top NASDAQ Biotech and Pharma Stocks: Constellation Leads

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
April 10, 2019

Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms

Sorrento Therapeutics (NASDAQ:SRNE) has announced results from its discovery study exploring potential benefits of resiniferatoxin in controlling neuro-inflammatory processes associated...
March 22, 2019

Sorrento Therapeutics Announces Merger of Scilex and Semnur

Sorrento Therapeutics (NASDAQ:SRNE) has announced its majority-owned subsidiary Scilex Pharmaceuticals will merge with Semnur Pharmaceuticals to form a new company,...
September 19, 2018

Scilex Announces Pricing and Availability of ZTlido for the Commercial Launch of its First Product in October of 2018

Scilex Pharmaceuticals a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE) announced that the Wholesale Acquisition Cost (WAC) for ZTlido (lidocaine topical...
September 10, 2018

Sorrento Therapeutics Subsidiary Scilex Receives New Funding

Sorrento Therapeutics announced on Monday that its subsidiary, Scilex Pharmaceuticals, has received US$140 million in funding.